Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus F Neurath

Showing results (531-540 of 676) with videos related to

Pageof 68
Sort By:
Therapeutic Advances in Gastroenterology|January 28, 2021
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximabSarah Fischer, Sarah Cohnen, Entcho Klenske, et al.
Cells|December 16, 2020
IgA2 Antibodies against SARS-CoV-2 Correlate with NET Formation and Fatal Outcome in Severely Diseased COVID-19 PatientsLéonie A N Staats, Hella Pfeiffer, Jasmin Knopf, et al.
Frontiers in Pharmacology|February 19, 2019
Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel DiseaseCharlotte Lichnog, Sha Klabunde, Emily Becker, et al.
Gastroenterology|July 29, 2019
Interferon Lambda Promotes Paneth Cell Death Via STAT1 Signaling in Mice and Is Increased in Inflamed Ileal Tissues of Patients With Crohn's DiseaseClaudia Günther, Barbara Ruder, Iris Stolzer, et al.
The Lancet. Gastroenterology & Hepatology|October 8, 2020
Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trialRaja Atreya, Laurent Peyrin-Biroulet, Andrii Klymenko, et al.
Gastroenterology|July 5, 2021
Targeting of the Tec Kinase ITK Drives Resolution of T Cell-Mediated Colitis and Emerges as Potential Therapeutic Option in Ulcerative ColitisKristina Lechner, Stefanie Mott, Ragheed Al-Saifi, et al.
Clinical and Translational Medicine|April 8, 2023
Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healingKatrin Sommer, Karin Heidbreder, Lucas Kreiss, et al.
Scientific Reports|November 3, 2024
Intestinal epithelial Gasdermin C is induced by IL-4R/STAT6 signaling but is dispensable for gut immune homeostasisReyes Gámez-Belmonte, Yara Wagner, Mousumi Mahapatro, et al.
Inflammatory Bowel Diseases|July 6, 2019
Environmental Microbial Factors Determine the Pattern of Inflammatory Lesions in a Murine Model of Crohn's Disease-Like InflammationIris Stolzer, Valentina Kaden-Volynets, Barbara Ruder, et al.
Therapeutic Advances in Gastroenterology|December 2, 2024
Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort studySarah Fischer, Moritz Donhauser, Sarah Cohnen, et al.
Pageof 68

Showing results (531-540 of 676) with videos related to

Sort By:
Pageof 68
Therapeutic Advances in Gastroenterology|January 28, 2021
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximabSarah Fischer, Sarah Cohnen, Entcho Klenske, et al.
Cells|December 16, 2020
IgA2 Antibodies against SARS-CoV-2 Correlate with NET Formation and Fatal Outcome in Severely Diseased COVID-19 PatientsLéonie A N Staats, Hella Pfeiffer, Jasmin Knopf, et al.
Frontiers in Pharmacology|February 19, 2019
Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel DiseaseCharlotte Lichnog, Sha Klabunde, Emily Becker, et al.
Gastroenterology|July 29, 2019
Interferon Lambda Promotes Paneth Cell Death Via STAT1 Signaling in Mice and Is Increased in Inflamed Ileal Tissues of Patients With Crohn's DiseaseClaudia Günther, Barbara Ruder, Iris Stolzer, et al.
The Lancet. Gastroenterology & Hepatology|October 8, 2020
Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trialRaja Atreya, Laurent Peyrin-Biroulet, Andrii Klymenko, et al.
Gastroenterology|July 5, 2021
Targeting of the Tec Kinase ITK Drives Resolution of T Cell-Mediated Colitis and Emerges as Potential Therapeutic Option in Ulcerative ColitisKristina Lechner, Stefanie Mott, Ragheed Al-Saifi, et al.
Clinical and Translational Medicine|April 8, 2023
Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healingKatrin Sommer, Karin Heidbreder, Lucas Kreiss, et al.
Scientific Reports|November 3, 2024
Intestinal epithelial Gasdermin C is induced by IL-4R/STAT6 signaling but is dispensable for gut immune homeostasisReyes Gámez-Belmonte, Yara Wagner, Mousumi Mahapatro, et al.
Inflammatory Bowel Diseases|July 6, 2019
Environmental Microbial Factors Determine the Pattern of Inflammatory Lesions in a Murine Model of Crohn's Disease-Like InflammationIris Stolzer, Valentina Kaden-Volynets, Barbara Ruder, et al.
Therapeutic Advances in Gastroenterology|December 2, 2024
Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort studySarah Fischer, Moritz Donhauser, Sarah Cohnen, et al.
Pageof 68